Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

ECI830

Name: ECI830
Brand: TargetMol
SKU: T204836
Rating: 4.5 (1 reviews)

(Synonyms: ECI 830, CDK2-IN-37) Copy Product Info

🥰Excellent

Synonyms: ECI 830, CDK2-IN-37

Catalog No. T204836 Copy Product Info

🥰Excellent

ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. ECI830 inhibits CDK2 activity and induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for research in HR+/HER2- breast cancer models and tumor systems with CCNE1 amplification, particularly in studies of CDK2-dependent cell-cycle regulation and proliferative signaling networks.

Cas No. 3054692-62-2

Pack Size	Price	USA Stock	Global Stock
1 mg	$283	10-14 weeks	10-14 weeks
5 mg	$676	10-14 weeks	10-14 weeks
25 mg	$1,550	10-14 weeks	10-14 weeks
100 mg	$3,380	10-14 weeks	10-14 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Product Introduction

Bioactivity

Description	ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. ECI830 inhibits CDK2 activity and induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for research in HR+/HER2- breast cancer models and tumor systems with CCNE1 amplification, particularly in studies of CDK2-dependent cell-cycle regulation and proliferative signaling networks.
In vitro	Methods:CCNE1-amplified ovarian cancer OVCAR3 cells and lung cancer H810 cells were selected to evaluate the in vitro antiproliferative effect of ECI830. Results:ECI830 exerted prominent antiproliferative activity against CCNE1-amplified ovarian and lung cancer cells [1].
In vivo	Methods:A xenograft model of drug-resistant HR+/HER2 breast cancer MCF7 cells was established. Monotherapy with ECI830 or ribociclib and combined medication were applied respectively. Signaling pathway activity, biomarker expression and tumor growth were compared among groups. Results:Combined treatment exerted synergistic efficacy compared with single drugs, presenting stronger pathway inhibition, more obvious biomarker regulation and remarkably enhanced tumor growth suppression [1].
Synonyms	ECI 830, CDK2-IN-37

Chemical Properties

Molecular Weight	384.43
Formula	C₁₉H₂₄N₆O₃
Cas No.	3054692-62-2
Smiles	O=C1C2(C=3C(N1[C@H]4C[C@H](O)CCC4)=NC(NC=5C(OCC)=NNC5)=NC3)CC2

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Related Tags: ECI830 chemical structure | ECI830 in vivo | ECI830 in vitro | ECI830 formula | ECI830 molecular weight